Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass

Circulation

Volumn 96, Issue 2, 1997, Pages 569-574

  Shigeta, Osamu ^a   Kojima, Hiroshi ^a   Jikuya, Tomoaki ^a   Terada, Yasushi ^a   Atsumi, Naotaka ^a   Sakakibara, Yuzuru ^a   Nagasawa, Toshiro ^a   Mitsui, Toshio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cardiopulmonary bypass; Fibrinolysis; Platelets; Surgery

Indexed keywords

ALPHA 2 ANTIPLASMIN; APROTININ; CARDIOPLEGIC AGENT; FIBRINOGEN RECEPTOR; HEPARIN; PADGEM PROTEIN; PLASMIN; PLASMINOGEN; THROMBIN; TRANEXAMIC ACID;

ADULT; AGED; ANTIGEN EXPRESSION; AORTA CLAMPING; ARTICLE; BLEEDING; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; FIBRINOLYSIS; FLOW CYTOMETRY; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE RICH PLASMA;

EID: 0030791587     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.2.569     Document Type: Article

References (27)

1. Bernabei A, Gikakis N, Kowalska MA, Niewiarowski S, Edmunds LH Jr. Iloprost and echistatin protect platelets during simulated extracorporeal circulation. Ann Thorac Surg. 1995;59:149-153.
2. FitzGerald GA. Dipyridamole. N Engl J Med. 1987;316:1247-1257.
3. Addonizio VP Jr, Strauss JF III, Colman RW, Edmunds LH Jr. Effect of prostaglandin E1 on platelet loss during in vitro cardiopulmonary bypass. Circ Res. 1979;44:350-357.
4. Teoh KH, Christakis GT, Weisel RD. Dipyridamole-preserved platelets and reduced blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1988;96:332-341.
5. Shigeta O, Gluszko P, Downing SW, Lu W, Niewiarowski S, Edmunds LH Jr. Protection of platelets during long-term extracorporeal membrane oxygenation in sheep with a single dose of a disintegrin. Circulation. 1992;86(suppl II):II-398-II-404.
6. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989;97: 364-372.
7. Havel M, Teufelsbauer H, Knobl P, Dalmatiner R, Jaksch P, Zwolfer W, Muller M, Vukovich T. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg. 1991;101:968-972.
8. Shinfeld A, Zippel D, Lavee J, Lusky A, Shinar E, Savion N, Mohr R. Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate. Ann Thorac Surg. 1995;59:872-876.
9. Tabuchi N, Huet RCG, Sturk A, Eijsman L, Wildevuur CRH. Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 1994;58: 1036-1039.
10. Liu B, Tengborn L, Larson G, Radberg LOG, Belboul A, Dernevik L, Roberts D. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operation. Ann Thorac Surg. 1995;59: 1534-1540.
11. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 1993;55: 1033-1041.
12. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33:479-496.
13. Kaller H, Patzschke K, Wegner LA, Horster FA. Pharmacokinetic observations following intravenous administration of radioactive labelled aprotinin in volunteers. Eur J Drug Metab Pharmacokinet. 1978;2:79-85.
14. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH Jr. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-10.
15. Gemmell CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J Lab Clin Med. 1995;125:276-287.
16. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990; 99:788-797.
17. Huang H, Ding W, Su Z, Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg. 1993;106:11-18.
18. Winters KJ, Eisenberg PR, Jaffe AS, Santoro SA. Dependence of plasmin-mediated degradation of platelet adhesive receptors on temperature and Ca+ . Blood. 1990;76:1546-1557.
19. Schafer AI, Maas AK, Ware JA, Johnson PC, Rittenhouse SE, Salzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest. 1986;78:73-79.
20. Gouin I, Lecompte T, Morel MC, Lebrazi J, Modderman PW, Kaplan C, Samama MM. In vitro effect of plasmin on human platelet function in plasma: inhibition of aggregation caused by fibrinogenolysis. Circulation. 1992;85:935-941.
21. Lu H, Soria C, Cramer EM, Soria J, Maclouf J, Perrot JY, Li H, Commin PL, Schumann F, Regnier O, Lijnen RH, Caen JP. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood. 1991;77:996-1005.
22. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;108:1083-1091.
23. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29:236-261.
24. Plow EF, Herren T, Redlitz A, Miles LA, Jane L, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J. 1995;9: 939-945.
25. Montrucchio G, Bergerone S, Bussolino F, Alto G, Sylvester L, Lucia E, Cravat A, Cravat M, Leo MD, Emanuelli G, Camussi G. Streptokinase induces intravascular release of platelet-activating factor on patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. Circulation. 1993; 88:1476-1483.
26. Parise P, Hauert J, Iorio A, Callegari P, Agnelli G. Streptokinase and rt-PA activate platelets on the rethrombosis rate after their administration in myocardial infarction. J Lab Clin Med. 1995;125: 212-221.
27. Torr SR, Eisenberg PR, Sobel BE. The dependence of activation of platelets by a plasminogen activator on the evolution of thrombin activity. Thromb Res. 1991;64:435-444.